LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial

Tarih
2016
Yazar
Masmiquel, Luis
Petrie, John R.
Marso, Steven P.
Bain, Stephen C.
Franek, Edward
Jacob, Stephan
Leiter, Lawrence A.
Haluzik, Martin
Omar, Mohamed
Shestakova, Marina
Van Gaal, Luc
Mann, Johannes F.
Baeres, Florian M. M.
Zinman, Bernard
Poulter, Neil R.
Satman, Ilhan
Üst veri
Tüm öğe kaydını göster
Özet
Objective: As glucagon-like peptide-1 receptor agonists lower blood pressure (BP) in type 2 diabetes mellitus (T2DM), we examined BP control in relation to targets set by international bodies prior to randomization in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial.
Bağlantı
http://hdl.handle.net/20.500.12627/74999
https://doi.org/10.1097/hjh.0000000000000890
Koleksiyonlar